9906342-2
IPOS

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 39/395, 38/00

A1

(11) International Publication Number: WO 98/58672

(43) International Publication Date: 30 December 1998 (30.12.98)

(21) International Application Number: PCT/US98/12773

(22) International Filing Date: 19 June 1998 (19.06.98)

(30) Priority Data:
60/050,276 20 June 1997 (20.06.97) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/050,276 (CIP)
Filed on 20 June 1997 (20.06.97)

(71) Applicant *(for all designated States except US)*: BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: ADELMAN, Burt [-/US]; Concord, MA (US).

(74) Agent: FENTON, Gillian, M.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CD154 BLOCKADE THERAPY FOR THERAPEUTIC PROTEIN INHIBITOR SYNDROME

(57) Abstract

Methods and compositions for attenuating or mitigating; suppressing; preventing; delaying onset of; or, reversing exogenous protein inhibitor syndromes, exemplified by clotting factor (e.g., Factor VIII) inhibitor syndromes. The described methods use a CD40:CD154 binding interruptor, such as CD154 blocking agent, to attenuate or ameliorate counter-adaptive, bioinhibitory humoral immunity directed against an exogenous protein of therapeutic value.